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Abstract
Background: Previous studies have implicated NF-κB signaling in both cutaneous development and oncogenesis.
However, these studies have been limited in part by the lethality that results from extreme over- or under-expression
of NF-κB in available mouse models. Even cre-driven tissue specific expression of transgenes, or targeted deletion of
NF-κB can cause cell death. Therefore, the present study was undertaken to evaluate a novel mouse model of
enhanced NF-κB activity in the skin.
Methods: A knock-in homologous recombination technique was utilized to develop a mouse model (referred to as
PD mice) with increased NF-κB activity.
Results: The data show that increased NF-κB activity leads to hyperproliferation and dysplasia of the mouse
epidermis. Chemical carcinogenesis in the context of enhanced NF-κB activity promotes the development of
keratoacanthomata.
Conclusion: Our findings support an important role for NF-κB in keratinocyte dysplasia. We have found that
enhanced NF-κB activity renders keratinocytes susceptible to hyperproliferation and keratoacanthoma (KA)
development but is not sufficient for transformation and SCC development. We therefore propose that NF-κB
activation in the absence of additional oncogenic events can promote TNF-dependent, actinic keratosis-like dysplasia
and TNF-independent, KAs upon chemical carcinogensis. These studies suggest that resolution of KA cannot occur
when NF-κB activation is constitutively enforced.
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Introduction
Despite significant progress, a full understanding of the
pathogenesis of squamous cell carcinoma (SCC) of the skin
has remained elusive. There is good evidence to support a key
role for the tumor suppressor, p53 in the surveillance of
keratinocytes excessively damaged by ultraviolet (UV) light
[1,2]. In addition there is evidence of mutations in the H-ras
oncogene [3], and dysregulation of the transcription factor NF-
κB [4–6] contributing to SCC. Therefore, it is clear that multiple
genes and pathways are important in the development of SCCs
of the skin.
The varied clinical spectrum observed in SCC is consistent
with the disease being triggered through multiple pathways.
Clinically, squamous cell carcinoma is thought to be the
endpoint of a continuum that starts with normal keratinocytes
that undergo premalignant changes producing an actinic
keratosis (AK) [7]. In time, a subset of actinic keratoses can
develop into SCCs. AKs are considered to be “pre-malignant”
lesions, whereas SCCs are malignant tumors with the potential
to metastasize. [8]. The exact sequence of events remains
unclear, and SCC itself shows variability in its clinical course. In
two recent publications, keratoacanthomata, which are known
to be rare in mice, have been reported [9,10].
Multiple studies have suggested that NF-κB is involved in the
development of cutaneous SCCs. The NF-κB family of proteins
is a group of inducible transcription factors consisting of homo-
and heterodimers formed from its five members: p50, p52, c-
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Rel, p65 (Rel A), and RelB [11]. The importance of NF-κB in
skin development, inflammation, and carcinogenesis has been
demonstrated in numerous studies in mice [12]. However, the
specific role of NF-κB in skin carcinogenesis is controversial.
The IκBα knockout mouse demonstrates a thickened epidermis
and increased keratin 16 expression, a marker of
hyperproliferation in the epidermis [13], suggesting that
increased NF-κB activity leads to hyperproliferative
keratinocytes and possibly tumorigenesis. This is supported by
in vitro studies showing that HaCaT keratinocyte cultures
overexpressing p65 have an increased proliferative rate and
anchorage independence in soft agar assays [14]. Constitutive
activation of the NF-κB pathway in Hairless mutant mice have
been shown to lead to increased ultraviolet-induced squamous
cell cancers [15]. These studies are consistent with the well-
documented pro-tumorigenic role of NF-κB in other organ
systems including the liver, blood and bone marrow, among
others [16].
In contrast there is also convincing evidence that NF-κB may
prevent tumorigenesis in some models of skin carcinogenesis.
For example, aggressive, metastatic SCC is observed in mice
transplanted with human keratinocytes expressing oncogenic
Ras and an inhibitor of NF-κB, the IκBα super repressor
(IκBαSR) [4]. More strikingly, expression of the IκBαSR in
mouse skin, under the control of keratin 5 promoter, leads to
spontaneous squamous cell carcinoma development, even in
the absence of oncogenic Ras [6]. Careful analysis of the role
of NF-κB in skin cancer has been hampered by issues of
embryonic lethality in mice lacking NF-κB, and redundancy
between NF-κB family members.
In the current study, we have utilized a novel mouse model,
termed the PD mouse, expressing activated NF-κB to examine
the in vivo effects of NF-κB on mouse skin [17]. The
phosphorylation of serine 276 on the NF-κB p65 subunit has
been previously shown to increase the transactivation potential
of NF-κB [18,19] through increased binding of the coactivator
CBP/p300 [20]. The importance of phosphorylation of this site
on p65 in vivo has been demonstrated through the
development of different knock-in mice expressing mutant p65
carrying different amino acids at position 276. In one knock-in
mouse (called the PA mouse) the serine at position 276 was
replaced with an alanine (S276A) thereby preventing
phosphorylation. The PA mouse has embryonic lethality [21].
The PD mouse with a phosphomimetic aspartate residue
replacing the serine at position 276 showed increased NF-κB
activity, resulting in a systemic hyperinflammatory state [17].
We have now utilized this PD mouse model to examine the role




This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the University Committee on Animal
Resources at the University of Rochester (Protocol #101225,
UCAR-2008-042R). Tumor endpoints were followed in order to
minimize suffering.
Mice
The PD knock-in allele was generated by homologous
recombination in TC1 ES cells (129Sv). Targeted ES clones
were injected into blastocysts. Chimeras were bred to C57/BL6
mice to transmit the targeted allele to yield heterozygous mice
[17]. Heterozygous littermate mice were mated to obtain
homozygous PD mice. The PD allele was identified during
genotyping through EagI digestion. The 5’ primer was TGC
GAC AAG GTG CAG AAA GGT ACA and the 3’ primer was
CCA GCT TCC GGA ACA CCT TGA TAG.
PD heterozygous mice were crossed with TNFR1 knockout
mice (tnfrsf1a-/-) and then backcrossed to obtain TNFR1-/- mice
that additionally expressed alleles for either RelA wild-type,
heterozygous PD, or homozygous PD. We have found that PD
homozygous mice can be rescued by knocking out TNFR1
[17].
Mice were housed in the University of Rochester School of
Medicine Vivarium in compliance with Institutional Animal Care
and Use Committee guidelines at each institution (Protocol
#101225, UCAR-2008-042R).
Histology
Hematoxylin and Eosin (H&E) staining of 4 micron sections
was prepared from tissue fixed in Bouin’s solution.
Immunohistochemistry was performed as follows: after
deparaffinizing the slides, the tissue sections were treated with
3% hydrogen peroxide (in methanol) for 10 min. After washing
with distilled water for 2 min (3X), the slides were placed in
citrate buffer (0.01 M) and heated to boiling for 10 min. The
slides were allowed to cool to room temperature. After rinsing
with PBS, primary antibody was added: CD3, CD4, CD8,
CD90.2 (kind gifts of Dr. Dan Kaplan, MD, PhD University of
Minnesota); F4/80 (CL 8940), B220 (CL8990), and Rat Isotype
Control Ig (CLCR2A00; Cedarlane Laboratories), Ki-67
(M7249; Dako, USA) at 4 degrees Celsius overnight.
Appropriate biotinylated secondary antibodies were purchased
from Vector Labs (Burlingame, CA). The Vectastain Elite ABC
Universal kit was used for detection (Vector Labs). Nickel
enhanced Diaminobenzidine was obtained from Pierce
Chemical (Rockford, IL; 34065). Slides were counterstained
with Gill’s Hematoxylin #3 (Sigma).
Total Skin Thickness, Subcutaneous Fat Thickness,
and Hair Follicle Quantification
Counts were obtained at 10X magnification and divided into
5 equal areas on the field of view. Twenty representative
sections were counted from at least two mice.
Chemical Carcinogenesis
Five week old mice were shaved. After one week, mice that
were in a resting hair cycle were treated with 7,12-
Dimethyl-1,2-Benzanthracene (DMBA; Sigma, St. Louis, MO)
dissolved in 100 microliters of acetone, which was applied to
the dorsal back skin. Mice were treated with 50 µg DMBA once
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at 6 weeks of age. One week after initiation, mice were treated
topically with 10 µg phorbol ester (TPA; Sigma) twice a week.
Papilloma and keratoacanthoma development were recorded
weekly. TPA treatment was discontinued after 9 months and
mice were followed for over one year. Numbers of papilloma
and keratoacanthoma were compared using standard of means
analysis. The data was examined by a Fisher’s Exact test and
Bernoulli’s Distribution.
Immunofluorescence studies:
Performed as previously described [22,23]. 5 µm sections of
formalin-fixed and paraffin-embedded tumor samples were
used. Following deparaffinization and rehydration, the sections
were incubated overnight with mouse monoclonal antibody to
Cytokeratin 13 (1:150 dilution; Santa Cruz Biotechnology), or
mouse monoclonal antibody to Cytokeratin 10 (1:200 dilution;
Santa Cruz Biotechnology). On the next day, after a wash with
PBS, the sections were incubated with secondary anti-mouse
antibody  (Alexa Fluor 568-conjugated goat anti-mouse IgG,
Invitrogen. 1:200 dilution) for two hours. After the sections were
counterstained with DAPI and cover slips were mounted, the
sections were examined with a fluorescent microscope with the
20X objective. Pictures were obtained with a Nikon E800 and
examined with Spot Advanced Version 4.6.
DNA Sequencing:
Total genomic DNA was isolated from 40 µm sections of
formalin-fixed and paraffin-embedded tumor samples using the
genomic DNA isolation kit (Catalog number AM1975,
Invitrogen). Standard PCR reactions to identify mutations at
codon 61 of Hras were performed using mouse Hras specific
primers: P1forward5¹ ctaagccgtgttgttttgcagg, P2reverse5'
cacctatggctagcccgtgag, P3forward5¹ ctcctaccggaaacaggtggt
and P4reverse5’ cttcgaggacatccatcagtac. The purified PCR
product was directly sequenced at the core facility at the
medical center of the University of Rochester.
Keratoacanthomata which did not have a codon 61 mutation
were further evaluated by analysis of codons 12 and 13.
mHras-Codon 12-13 P1forward5’ ctaagtgtgcttctcattgg, mHras-
Codon13 P1reverse5’ acccatgaccactgccacagccc, mHras-
Codon12-13 P2forward5’ caggtggggcaggagctcctg, mHras-
Codon12-13-P2reverse5’ cctctggcaggtaggcagag. For Tp53
gene sequencing, we used multiple primers: for Exons3-4,
P1forward5¹ aggaaatcaggaactaactc, P2reverse5¹
ggcattgaaaggtcacacga, P3forward5’ :ctctctgctcttgttttccag,
P4reverse5¹ ggtcacacgaaagacaactc; For exons 5-6, P1-
forward5¹ tcattagttccccaccttga, P2reverse5¹
cacctctaagcctagctagc, P3forward5¹ cacctgatcgttactcggct,
P4rev: ctcaggagggtgaggcaa. For exon 7 and 8, P1forward5’
gctgcaggtcacctgtagtg, P2reverse5¹ aggtgactttggggtgaagc,
P3forward5¹ gaggtagggagcgacttcac and P4reverse5¹
tcaacaggctcctccgcctc. PCR products were directly sequenced
as described above.
Results
Importance of p65 Serine 276
We studied the knock-in mouse expressing a mutant p65
with a proline at position 275 and the serine mutated to aspartic
acid at position 276 (PD mouse), as previously described
[17,21]. The knock-in strategy at exon 7 led to two changes in
the RelA gene: 1) An EagI restriction site is incorporated to
allow genotyping to distinguish the PD mouse from wild-type
and 2) the codon TCT encoding serine 276 is changed to GAC,
encoding an aspartate (Figure 1A). Only PD alleles have an
EagI site thereby allowing differentiation of both mouse alleles
as either wild-type or PD (Figure 1B). The PD homozygous
mice are born in fewer numbers than their wild-type littermates
with approximately 50% decrease in the expected Mendelian
ratios (Figure 1C). It was previously reported that PD mice
litters have typical Mendelian ratios [17]. The reason for this
discrepancy is unclear. The mice were bred in different mouse
facilities, suggesting an environmental contribution, although
both colonies were in microisolator cages in specific pathogen-
free conditions. We have now had 6 years of breeding with the
colony. Because of the importance of NFκB in multiple events
of early developmental events, it is not surprising that elevated
levels would lead to embryonic death [24].
The PD homozygous mice are runted and most die within
two weeks of birth. At two weeks of age, PD homozygotes
display scaling, erythema, and alopecia of the skin (Figure 1C).
The majority of the inflammatory cells are F4/80 positive
macrophages, which are infrequently observed in wild-type
littermates. CD3, CD4, CD8, CD90.2, and B220 staining
showed no difference between the two groups (data not
shown). Positive control for all antibodies was assured using
mouse spleen (Figure 1D). At birth, there is no histological
distinction between the skin of PD homozygotes and
littermates, but by two weeks there are noticeable differences.
Homozygous PD mice show a thickened epidermis, decreased
numbers of hair follicles which are minaturized and amount of
subcutaneous fat, and the presence of dermal inflammatory
infiltrates (Figure 2).
Epidermal dysplasia and proliferation in homozygous
PD mice
While initially studying the skin of homozygous PD mice at
various ages from birth through death, we observed distinct
areas of epidermal dysplasia in untreated mice (Figure 3A).
Dysplastic areas consisted of large aggregates of basaloid
cells, which had not disrupted the basement membrane. Areas
of dysplasia were usually associated with acanthosis and were
more common in older mice. Histologically, the lesions were
most similar to the histologic changes observed in actinic
keratoses in humans. These dysplastic lesions were
independent of the inflammatory cell infiltrate, as there was no
correlation between the degree of inflammation and the
presence of dysplasia in 20 PD homozygous mouse skins
analyzed (not shown).
Because we identified a thickened epidermis and squamous
dysplasia in PD homozygous mice, we next examined whether
there was increased proliferative activity. As shown in Figure
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Figure 1.  Generation of PD mice.  Targeted knock-in at RelA to generate a S276D amino acid transition from exon 7 in mice
creating the PD targeting vector. A. Strategy for generating the targeted knock-in including the coding change at serine 276 and
addition of an EagI restriction site to allow for genotyping. B. Genotyping of the PD mouse shows a 722 base pair (bp) cDNA in the
wild-type mouse that can be cut in to two pieces (356 and 366 bp) with EagI in the presence of the PD allele. C. Homozygous PD
mice are born in fewer numbers than expected by normal Mendelian ratios. C. Approximately 10 day old littermates from a male and
female heterozygous PD breeding. Homozygous PD mice are runted, erythrodermic, alopecic, and scaly. At this point in
development, wild-type littermates demonstrate normal hair growth and size. D. Immunohistochemistry staining of mouse skin
showing few F4/80+ cells in wild-type tissue (left) compared to the large infiltrate in PD homozygous mouse skin (middle). Spleen
shows typical F4/80+ staining as a control (right).
doi: 10.1371/journal.pone.0071887.g001
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Figure 2.  Histology of PD mouse skin.  (H and E) A. The PD homozygous mouse skin at 10 days (right) has a thickened
epidermis, a significant inflammatory infiltrate, decreased subcutaneous fat and fewer hair follicles compared to the wild-type
littermates (left). B. The subcutaneous fat is decreased in the PD mouse skin and the total skin thickness is also diminished. The
number of hair follicles is decreased.
doi: 10.1371/journal.pone.0071887.g002
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Figure 3.  Proliferation and Dysplasia of PD mouse skin.  A. Homozygous PD mouse skin at 10 days showing focus of
epidermal dysplasia with aggregates of basaloid cells in the epidermis without penetration of the basement membrane. B.
Examination of proliferation of epidermal keratinocytes in mouse skin with Ki-67. Nuclear Ki-67 is restricted to the basal
keratinocytes in wild-type littermate controls (top) whereas the PD homozygous mouse has positive staining at all levels of the
epidermis (bottom). Skin treated with a rat isotype control shows no non-specific staining in the epidermis (not shown).
doi: 10.1371/journal.pone.0071887.g003
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3B, Ki-67 staining shows that PD homozygous keratinocytes
had proliferating cells throughout the full thickness of the
epidermis. This is in sharp contrast to the epidermis of wild-
type mice, in which proliferating cells are confined primarily to
the basal layer (Figure 3B).
PD heterozygous mice develop keratoacanthomas in
response to chemical carcinogens
Since the homozygous PD mouse showed an increase in
epidermal thickness, keratinocyte hyperproliferation, and areas
of squamous dysplasia, we were interested in examining if
these changes could lead to enhanced tumorigenesis. As
homozygous PD mice die at two weeks of age, we focused our
experiments on heterozygous PD mice. Heterozygotes
maintain normal control of NF-κB function through the inhibitor
IκB, are visually indistinguishable from controls, and have a
normal lifespan making the chemical carcinogenesis
experiments possible.
We therefore proceeded with tumor promotion studies that
would activate NF-κB and allow us to examine how enhanced
NF-κB signaling affects tumorigenesis in PD mice.
Ten wild-type littermates and ten heterozygous PD mice
were studied. Papilloma formation was similar between wild-
type and heterozygous PD mice and present in all mice (Figure
4A). Papilloma had a characteristic clinical appearance (Figure
4B) Over the course of the experiment, we observed the
development of keratoacanthomata (KAs) in 33% (3/9) of
heterozygote PD mice compared to 0% (0/10) of wild-type
littermates. The KAs formed after 30 weeks of TPA treatment,
with a range of 30 to 45 weeks. None of the KAs were noted to
have derived from pre-existing papilloma, which occurred
earlier than the KAs. In several mice, the tumors could be
followed (as they grew slowly) even after the TPA was
withdrawn. None of the KAs resolved even after the removal of
TPA for up to 5 months. Identical to those recently reported,
the tumors were crateriform masses filled with compact keratin
and lined by proliferative stratified squamous epithelium [9,10].
One PD heterozygote died of an unrelated event during the
course of the experiment and did not complete the study. The
tumors showed classic clinical and histologic appearance with
a keratinaceous core and well-defined borders (Figure 4C and
D). Gross examination of the liver and lungs showed no
abnormalities. Histological evaluation of the skin and any
enlarged lymph nodes, showed no penetration of the tumor
through the basement membrane or lymph node involvement,
respectively (data not shown). Moreover, despite the large size
of the tumors, mice continued to feed, groom, and behave
normally.
The mouse tissue from the chemical carcinogenesis studies
was examined for mutations in Hras and Tp53 (Figure 4E). PD
heterozygote skin from normal appearing areas of skin did not
show mutations in Hras. All skin samples tested, which showed
papillary hyperplasia or papillomas had Hras mutations with an
A→T transversion (182) at codon 61 [25]. In the
keratoacanthomata, one of the three mice was found to have a
codon 61 mutation. In keratoacanthomata where no Hras
mutation was observed in codon 61, codons 12 and 13 were
also examined. No mutations in Hras codons 12 or 13 were
discovered. Therefore 2 of 3 keratoacanthomata had no
identified Hras mutation. Tp53 mutations were not identified in
any of the tissues sampled, including none in the papilloma or
keratoacanthoma.
Although the keratoacanthomata were not observed to have
developed from papillomas, we evaluated keratin stains for the
typical transition from papilloma to SCC. Typically this
transition leads to an downregulation of keratin 10 (K10) and
upregulation of keratin 13 (K13) [25]. Examination of keratin 10
and 13 expression of the mouse tumors showed that K10
expression was strong in papilloma while there was moderate
staining in the keratoacanthomata (Figure S1). Therefore some
of the keratoacanthomata maintained this marker of benign
keratinocytes. The K13 expression was also strong in the
papillomas. In two keratoacanthomata shown, one had patchy
staining of K13 while the other was more homogenous (Figure
S1). The variability in K13 expression in the keratoacanthomata
might suggest that these tumors behave less like SCCs (which
express K13).
Statistical analysis of tumor formation in TPA-treated control
versus PD mice was initially performed by applying Fisher’s
exact test to the 2 x 2 contingency table of treatment by
keratoacanthomata (p = 0.09). Due to the rarity of
keratoacanthomata in mice, we also carried out a 1-sided exact
binomial test of the null hypothesis that the incidence of
keratoacanthoma is at most 1%. Under this null hypothesis, the
probability of having at least 3 mice with keratoacanthoma
among 9 treated mice is p = 0.00008. In fact, the 95% 1-sided
lower Clopper-Pearson confidence bound for the incidence of
keratoacanthoma is 9.77%.
Keratoacanthoma development in heterozygous PD
mice is TNFR1 independent
It was previously shown that the majority of the genes
upregulated in the PD mouse is due to NF-κB activation
through the TNF receptor 1 [17]. The relaPD/PD tnfrsf1a-/- live
longer than the relaPD/PD mice. Approximately half of the
relaPD/PD tnfrsf1a-/- mice survive, beyond 6 months of age. To
focus on the effect of the PD allele on skin tumorigenesis in the
absence of concomitant inflammation or TNFR1 signaling, we
utilized PD homozygous (relaPD/PD tnfrsf1a-/-), PD heterozygous
(relaPD/wt tnfrsf1a-/-), and p65 wild-type (relawt/wt tnfrsf1a-/-) mice
for chemical carcinogenesis studies. All mice, which were age
5 weeks, appeared normal and lacked skin inflammation at the
outset of the study (Figure 5A). PD homozygous mice (relaPD/PD
tnfrsf1a-/-) started to die at approximately one month of
treatment. The cause of death was unclear, but was not related
to tumor burden. All 10 relaPD/PD tnfrsf1a-/- died within 2 months
of treatment. Because the relaPD/PD tnfrsf1a-/- have an
underlying liver inflammation [17], we hypothesize that the
relaPD/PD tnfrsf1a-/- mice die because they are unable to detoxify
the TPA [26], although the exact cause of death remains to be
determined. Regardless, the lethality necessitated that this
experiment be performed using heterozygous relaPD/wt tnfrsf1a-/-
and wild-type relawt/wt tnfrsf1a-/- mice.
The two groups of mice showed a similar incidence of
papillomata to that observed in the previous experiment in mice
expressing TNFR1 (data not shown). No squamous cell
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Figure 4.  Keratoacanthoma development in the PD mice.  Chemical carcinogenesis study in heterozygous PD and wild-type
littermates. A. Papilloma formation in a PD heterozygote during TPA treatment shows no difference between experimental and
control groups of mice. B. Clinical appearance of a typical papilloma. C. PD heterozygous mouse that has developed a typical
keratoacanthoma showing a keratinaceous core and well-defined tumor. D. Histologic examination of keratoacanthomata from PD
heterozygous mice showing classic appearance of these tumors. E. Mutational analysis of PD mice for Hras codons 12,13,61 and
Tp53.
doi: 10.1371/journal.pone.0071887.g004
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carcinomas developed during the entire experiment but two of
ten relaPD/wt tnfrsf1a-/- mice developed keratoacanthomata
(Figure 5B). This may indicate that keratoacanthoma
development is at least partly independent from TNF signaling.
However because there were fewer KAs in the relaPD/wt
tnfrsf1a-/- mice compared to relaPD/wt mice and the sample size
was small, it is difficult to exclude the possibility that TNF
signaling may partly contribute to KA development. Future
studies will further explore these pathways. One of the
keratoacanthomata had an Hras mutation at codon 61 while
the other did not. There were no Hras mutations at codons 12
or 13 or Tp53 found.
Due to the rarity of keratoacanthomata in mice, we again
carried out a 1-sided exact binomial test of the null hypothesis
that the incidence of keratoacanthoma is at most 1%. Under
this null hypothesis, the probability of having at least 2 mice
with keratoacanthoma among 10 treated mice is p= 0.004.
Figure 5.  Keratoacanthoma development in the PD mice in the absence of TNF signaling.  Chemical carcinogenesis study in
which PD heterozygotes and littermates lack TNFR1 expression. A. relaPD/PD tnfrsf1a-/- knockout skin is normal histologically
compared to RelA tnfrsf1a-/-. B. Summary findings among various genotypes, representing evaluation of 20 mice in each cohort
except for the PD homozygous cohort, which included 10 mice. C. Mutational analysis of PD mice for Hras and Tp53.
doi: 10.1371/journal.pone.0071887.g005
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Discussion
The study of NF-κB function in the skin has been
complicated by both the redundancy among family members
and the embryonic lethality that can result from manipulation of
NF-κB signaling pathway genes. For this reason transgenic
mice expressing RelA have either had expression restricted to
particular cell types or were not compatible with life [27,28].
The PD mouse exhibits enhanced NF-κB-induced
transcriptional responses while still being subject to the primary
homeostatic mechanism controlling NF-κB activity, namely
inhibition by IκB [17]. Homozygous PD mice develop an
inflammatory skin condition associated with infiltration of
F4/80+ macrophages. These mice develop skin with decreased
hair follicle number and thinning of the subcutaneous fat.
Because of the important role of NF-κB in a number of
cancers, and the lack of clarity regarding the role of NF-κB in
skin carcinogenesis, we examined the tumorigenic potential of
skin with enhanced NF-κB activity. Although some models
have shown that NF-κB inhibits tumor development in the skin,
it has not been clear how these results are to be reconciled
with the accepted role of NF-κB as a pro-tumorigenic factor in
many other tissues [4,6,29]. Our results provide some
additional insight. Enhanced NF-κB activity in the PD
homozygous mice also leads to foci of epidermal dysplasia.
Intriguingly, the hyperplasia with increased epidermal thickness
and enhanced Ki-67 staining in PD homozygous mice was not
correlated with histological evidence of inflammation. We have
not ruled out the possibility that the hyperproliferation observed
in the PD homozygous mice is due to a continuous stimulation
of basal keratinocytes by inflammatory cells, as has been
previously reported in the K5-IKK2 transgenic mouse [30].
Regardless, because the same keratinocyte hyperproliferation
and dysplasia was not observed in the homozygous relaPD/PD
tnfrsf1a-/- mice, it is clear that TNF contributes to the
development of these lesions. p65PD-driven cytokine production
or hyper-responsiveness to normal skin cytokine milieu, even in
the absence of a cellular inflammatory infiltrate, could be
responsible for the acanthosis observed in relaPD/PD tnfrsf1a+/+
but not relaPD/PD tnfrsf1a-/- mice.
It has previously been reported that when NF-κB is inhibited
through overexpression of IκB or deletion of IKK2 in basal layer
keratinocytes, there is hyperproliferation and increased Ki-67
staining observed [31,32]. However, in both of these models,
keratinocyte hyperproliferation appeared to be induced by
immune infiltrates – perhaps as a consequence of keratinocyte
death and barrier dysfunction. Thus inhibition of canonical NF-
κB signaling in keratinocytes has, as a primary consequence,
the induction of inflammation with hyperplasia being a
secondary response to the resulting inflammatory state. NF-κB
activity also apparently has an important role in differentiation
of basal keratinocytes to non-proliferating supra-basal
keratinocytes. When this developmental program is affected by
aberrant NF-κB signaling, it sometimes results in well-
differentiated keratoacanthomata (Table 1). The dysplasia and
hyperproliferative phenotype can be reversed by deleting
TNFR1. Therefore, consistent with previous reports [33], it
appears that this pathway is important for keratinocyte
proliferation.
We report here that increased NF-κB activity in mouse skin
leads to production of keratoacanthomata in response to
chemical carcinogenesis. Although in humans some
keratoacanthomata can disappear over time without treatment,
the keratoacanthomata in the PD mice did not resolve or
decrease in size after 5 months without treatment. These
findings suggest that keratoacanthoma development may be
distinct from SCC development. Whereas the tumor suppressor
activities of NF-κB may be protective against developing
invasive SCCs as shown in other reports [34], it is possible that
formation of keratoacanthomata through a non-oncogenic
proliferative pathway is promoted.
One alternative explanation of our findings would be that the
tumors we have identified as KAs are actually well-
differentiated squamous cell carcinomas that do not progress,
perhaps due to the progression resistance of the C57BL/6
background. This would support that NF-κB expression may
play a role in SCC formation at least in well-differentiated, early
SCCs. Whereas in later, invasive SCCs, a downregulation of
NF-κB is important [4]
The role of NF-κB in the development of cutaneous
carcinogenesis has previously been investigated by several
groups. In contrast to the accepted view of NF-κB as
supporting carcinogenesis, tumor proliferation and survival, a
murine model in which NF-κB activity is constitutively inhibited
through the expression of the IκBα super-repressor
(K5IκBαSR) demonstrates spontaneous SCC development [6].
Interestingly the tumors in K5IκBαSR mice were TNFR1
dependent [31], whereas the relaPD/wt tnfrsf1a-/- mice continue to
develop KAs although perhaps at lower numbers (Figure 5C).
In the study by van Hogerlinden, the K5-promoter transgene
drives expression of the IκBα super-repressor in basal layer
keratinocytes, restricting NF-κB inhibition to those cells. In
Table 1. NF-κB activity in the Skin.
 
TNF Independent NF-κB Activity in the Epithelium
Mouse p65 Outcome Reference
K5-IKK2 ↑ Hyperproliferation Page, et al 2010 & 2011
K5-IκBαSR ↓ TPA Induced Hyperproliferation Sur, et al 2009
IκBαK5KO/K5KO* ↑ Hyperproliferation/ K6 expression Rebholz, et al 2007
PD/PD ↑ Keratoacanthoma Poligone (current)
TNF Dependent NF-κB Activity in the Epithelium
Mouse p65 Outcome Reference
RelA-/- ↓ Hyperproliferation Zhang, et al 2005
K14-IKK2-/- ↓ Hyperproliferation Pasparakis, et al 2002
K14-NEMO-/- ↓ Hyperproliferation Nenci, et al 2006
K5-IκBαSR ↓ SCC Lind, et al 2004
*TNF independent in the presence of normal LT function NF-κB signaling in the
skin can at times be paradoxical. Both increased and decreased function of NF-κB
can lead to proliferation of skin keratinocytes. TNF receptor signaling is one factor
that can determine the outcome. Nevertheless there is TNF receptor independent
signaling of NF-κB that is important in the proliferative state of the keratinocyte.
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contrast, the p65S276D protein has enhanced activity in all
keratinocytes. Therefore although NFκB inhibition in the
epidermis can trigger a TNF-dependent inflammation that leads
to impaired differentiation, epidermal hyperplasia and SCC, it is
also possible that increased NF-κB activity in the skin can
cause a TNF-independent proliferation leading to
keratoacanthoma development (Table 1). Moreover although
the various experiments may appear contradictory in terms of
hyperproliferation of keratinocytes [4,12,35], there is a crucial
point of consistency: namely, that both inhibition and activation
of NF-κB in keratinocytes can drive epidermal inflammation
[29].
This complexity in the phenotypes is highlighted when
considering the work of Pasparakis and Page, who deleted or
overexpressed IKKβ in mouse epidermis, respectively. Both
models showed development of skin inflammation and
hyperplasia [32,36]. The K5-IKKβ transgenic mouse, which like
the PD mouse has increased NF-κB signaling, has recently
been shown to develop keratinocyte tumors of the oral mucosa
[37]. Similarly to the PD mouse, tumors occurred even after
disruption of the TNF pathway and these keratinocyte tumors
maintained the integrity of the basal membrane. This supports
our model that increased NF-κB activity in keratinocytes leads
to a TNF-independent tumor formation which remains limited to
the basal membrane. In this scenario both proliferation and
inflammation likely are the direct result of activation of NF-κB
within the keratinocyte. In contrast, inhibition of the pathway
leads to proliferation and atypia that is secondary to
keratinocyte death and resulting inflammation, and is,
therefore, TNF dependent.
Lastly the development of KAs in the PD mouse was
unexpected. This model should help us to better understand
this unique skin tumor. Given that KAs in the PD mouse do not
self-resolve, we speculate that resolution would normally
require termination of NF-κB activity. There are KA types that
do not resolve [38] and our data may suggest that NF-κB
activation might selectively trigger this particular subset of KA.
Future studies will address the requirement of continued NF-κB
activation for KA stability in the PD mouse. As we did not
observe any progression of the KAs, our data suggest that KAs
are not on a spectrum with SCCs. This has been supported by
a comparative genomic comparison of KAs and SCCs [39].
Moreover there appears to be no required genetic signature in
the KAs studied other than expression of the PD allele as some
KAs had a normal Hras and Tp53.
In summary, the role of NF-κB activity in keratinocyte
maturation and proliferation remains incompletely resolved.
The current models provide evidence for a role for NF-κB, both
with enhanced or suppressed activity, in the development of
epidermal thickening, proliferation, and tumorigenesis
(13,31,14,32,33). Clearly the pathways contributing to these
processes must be further explored. Here we provide a
hypothetical model suggesting the existence of two distinct
pathways involving NF-κB, one leading to oncogenesis and/or
transformed cell survival and the other accounting for non-
oncogenic proliferation. Future efforts will examine the role of
NF-κB in other cutaneous benign or malignant proliferative
conditions and model systems.
Supporting Information
Figure S1.  Keratin 10 and 13 staining of PD mouse
tumors. Mouse tumors were stained for K10 and K13. In three
mouse papillomas there was strong staining for K10 and K13.
In two keratoacanthomata stained there was weak to patchy
K10 and patchy to homogenous K13.
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